Article Text

Download PDFPDF
Percutaneous coronary revascularisation: is it ever worth what it costs?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Conflict of interest:

    Consulting: All <10k

    Aventis, Bridgewater, New Jersey, USA

    AstraZeneca, London, UK

    Medtronic, Inc., Minneapolis, Minnesota, USA

    Novartis, East Hanover, New Jersey, USA

    Research Grants: All >10k

    National Institutes of Health/National Heart, Lung, and Blood Institute

    National Institutes of Health/Agency for Healthcare Research and Quality

    Proctor & Gamble, Cincinnati, Ohio, USA

    Pfizer, New York City, New York, USA

    Medtronic, Inc., Minneapolis, Minnesota, USA

    Alexion Pharmaceuticals, Inc., Cheshire, Connecticut, USA

    Medicure, Winnipeg, Manitoba, Canada

    Miscellaneous: >10k

    Mosby, St. Louis, Missouri, USA, American Heart Journal Editor

  • Abbreviations:
    acute coronary syndrome(s)
    coronary artery disease
    myocardial infarction
    percutaneous coronary intervention, QALY, quality-adjusted life year

Linked Articles